NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock - Currency: USD
NASDAQ:ARTL (5/2/2025, 9:38:24 AM)
1.015
+0 (+0.5%)
The current stock price of ARTL is 1.015 USD. In the past month the price increased by 14.77%. In the past year, price decreased by -25.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 59.99 | 782.57B | ||
JNJ | JOHNSON & JOHNSON | 15.51 | 375.56B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 20.05 | 307.89B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.79 | 226.38B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.31 | 222.67B | ||
MRK | MERCK & CO. INC. | 10.8 | 211.70B | ||
PFE | PFIZER INC | 7.54 | 137.18B | ||
SNY | SANOFI-ADR | 14.38 | 135.92B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.79 | 101.41B | ||
GSK | GSK PLC-SPON ADR | 7.15 | 79.76B | ||
ZTS | ZOETIS INC | 26.92 | 71.08B | ||
HLN | HALEON PLC-ADR | 22.07 | 48.80B |
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 6 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
ARTELO BIOSCIENCES INC
505 Lomas Santa Fe, Suite 160
Solana Beach CALIFORNIA 92037 US
CEO: Gregory D. Gorgas
Employees: 5
Company Website: https://artelobio.com/
Investor Relations: https://ir.artelobio.com/
Phone: 18589257049
The current stock price of ARTL is 1.015 USD. The price increased by 0.5% in the last trading session.
The exchange symbol of ARTELO BIOSCIENCES INC is ARTL and it is listed on the Nasdaq exchange.
ARTL stock is listed on the Nasdaq exchange.
9 analysts have analysed ARTL and the average price target is 5.61 USD. This implies a price increase of 452.71% is expected in the next year compared to the current price of 1.015. Check the ARTELO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARTELO BIOSCIENCES INC (ARTL) has a market capitalization of 3.33M USD. This makes ARTL a Nano Cap stock.
ARTELO BIOSCIENCES INC (ARTL) currently has 5 employees.
ARTELO BIOSCIENCES INC (ARTL) has a support level at 0.97 and a resistance level at 1.05. Check the full technical report for a detailed analysis of ARTL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARTL does not pay a dividend.
ARTELO BIOSCIENCES INC (ARTL) will report earnings on 2025-05-08.
ARTELO BIOSCIENCES INC (ARTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.05).
The outstanding short interest for ARTELO BIOSCIENCES INC (ARTL) is 26.92% of its float. Check the ownership tab for more information on the ARTL short interest.
ChartMill assigns a technical rating of 2 / 10 to ARTL. When comparing the yearly performance of all stocks, ARTL is a bad performer in the overall market: 77.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ARTL. ARTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -3.05. The EPS increased by 4.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -209.15% | ||
ROE | -343.93% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to ARTL. The Buy consensus is the average rating of analysts ratings from 9 analysts.